Biodexa Pharmaceticals Stock Filter Stocks by Fundamentals
| BDRX Stock | 4.35 0.44 11.25% |
By evaluating key metrics such as revenue growth, profitability, cash flow trends, and balance sheet strength, investors can better assess Biodexa Pharmaceticals' long-term financial health and intrinsic value.
Biodexa | Shares Owned by Insiders | Build AI portfolio with Biodexa Stock |
Biodexa Pharmaceticals Current Valuation Drivers
We derive many important indicators used in calculating different scores of Biodexa Pharmaceticals from analyzing Biodexa Pharmaceticals' financial statements. These drivers represent accounts that assess Biodexa Pharmaceticals' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Biodexa Pharmaceticals' important valuation drivers and their relationship over time.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Market Cap | 8.5M | 4.8M | 1.0M | 163.2K | 20.0M | 13.6M | |
| Enterprise Value | 1.2M | (4.5M) | (1.2M) | (5.3M) | 19.1M | 20.1M |
Biodexa Fundamentals
| Return On Equity | -0.62 | ||||
| Return On Asset | -0.39 | ||||
| Current Valuation | (2.21 M) | ||||
| Shares Outstanding | 619.52 K | ||||
| Shares Owned By Insiders | 0.95 % | ||||
| Shares Owned By Institutions | 7.18 % | ||||
| Number Of Shares Shorted | 38.91 K | ||||
| Price To Book | 0.16 X | ||||
| Price To Sales | 0.58 X | ||||
| Gross Profit | (4.91 M) | ||||
| EBITDA | (9.08 M) | ||||
| Net Income | (5.73 M) | ||||
| Total Debt | 727 K | ||||
| Book Value Per Share | 18.46 X | ||||
| Cash Flow From Operations | (12.26 M) | ||||
| Short Ratio | 0.28 X | ||||
| Earnings Per Share | (26.21) X | ||||
| Target Price | 178.3 | ||||
| Number Of Employees | 13 | ||||
| Beta | 0.95 | ||||
| Market Capitalization | 2.69 M | ||||
| Total Asset | 14.78 M | ||||
| Retained Earnings | (150.42 M) | ||||
| Working Capital | 3.78 M | ||||
| Net Asset | 14.78 M |
About Biodexa Pharmaceticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Biodexa Pharmaceticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Biodexa Pharmaceticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Biodexa Pharmaceticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Biodexa Stock Analysis
When running Biodexa Pharmaceticals' price analysis, check to measure Biodexa Pharmaceticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biodexa Pharmaceticals is operating at the current time. Most of Biodexa Pharmaceticals' value examination focuses on studying past and present price action to predict the probability of Biodexa Pharmaceticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biodexa Pharmaceticals' price. Additionally, you may evaluate how the addition of Biodexa Pharmaceticals to your portfolios can decrease your overall portfolio volatility.